8-K: Inovio Pharmaceuticals Reports Q1 2025 Financial Results, Remains on Track for INO-3107 BLA Submission

Inovio Pharmaceuticals announces its Q1 2025 financial results and provides an update on the progress of its INO-3107 program and DMAb technology.

Summary

• Inovio Pharmaceuticals reported its financial results for the first quarter of 2025.
• The company is on track to begin a rolling submission of the Biologics License Application (BLA) for INO-3107 in mid-2025, seeking approval as a treatment for recurrent respiratory papillomatosis (RRP).
• Device design verification (DV) testing for the CELLECTRA device, required for the BLA submission, is underway and expected to be completed in the first half of 2025.
• Clinical and immunological results from a Phase 1/2 trial of INO-3107 were published in Nature Communications in February 2025.
• Interim results from a Phase 1 trial of DNA-encoded monoclonal antibodies (DMAbs) showed promising results, with the data available as a preprint on ResearchSquare.com.
• Research and Development (R&D) expenses decreased to $16.1 million from $20.9 million for the same period in 2024.
• General and Administrative (G&A) expenses decreased to $9.0 million from $10.6 million for the same period in 2024.
• Total operating expenses decreased to $25.1 million from $31.5 million for the same period in 2024.
• Net loss decreased to $19.7 million, or $0.51 per share, from $30.5 million, or $1.31 per share, for the same period in 2024.
• As of March 31, 2025, Inovio had $68.4 million in cash, cash equivalents, and short-term investments, compared to $94.1 million as of December 31, 2024.
• Inovio estimates its current cash balance will support operations into the first quarter of 2026.
• The company projects an operational net cash burn of approximately $22 million for the second quarter of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress on INO-3107, promising DMAb data, and reduced net loss. However, the decreasing cash balance and potential need for future capital raises temper the optimism.

Positives

• Inovio is on track to submit the BLA for INO-3107, a potential treatment for RRP, with a goal to begin rolling submission in mid-2025.
• The company plans to request priority review of its BLA for INO-3107, which, if granted, could lead to an FDA approval decision in mid-2026.
• Interim results from the Phase 1 trial of DMAbs showed durable in vivo antibody production, with 100% of participants maintaining biologically relevant levels of DMAbs at week 72.
• The company's net loss decreased significantly in Q1 2025 compared to Q1 2024.
• Inovio believes INO-3107 could be the preferred product for patients and providers, if approved.

Negatives

• Cash, cash equivalents, and short-term investments decreased from $94.1 million as of December 31, 2024, to $68.4 million as of March 31, 2025.
• The company projects an operational net cash burn of approximately $22 million for the second quarter of 2025.

Risks

• The company's projections do not include any further capital-raising activities that Inovio may undertake.
• The forward-looking statements are subject to uncertainties inherent in clinical trials, product development programs, and commercialization activities.
• The availability of funding to support continuing research and studies is a risk factor.
• The adequacy of capital resources is a risk factor.
• There is no assurance that any product candidate will be successfully developed, manufactured, or commercialized.

Future Outlook

Inovio estimates its current cash, cash equivalents, and short-term investments balances will support the company's operations into the first quarter of 2026, with an operational net cash burn estimate of approximately $22 million for the second quarter of 2025. These projections do not include any further capital-raising activities that Inovio may undertake.

Management Comments

• Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer, stated that the company remains on track to submit its BLA for INO-3107 this year, with a goal to begin rolling submission in mid-2025.
• Dr. Shea also mentioned that if they receive priority review, it could allow for a PDUFA date in mid-2026.
• Dr. Shea expressed excitement about the promising data from a proof-of-concept Phase 1 clinical trial with their next-generation DMAb technology, as well as the potential of their entire DNA medicines pipeline.

Industry Context

Inovio is focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, which places them in the competitive landscape of gene therapy and vaccine development. The progress of INO-3107 is particularly relevant in the context of treatments for recurrent respiratory papillomatosis (RRP), where there is a need for non-surgical therapeutic options.

Comparison to Industry Standards

• The reported decrease in R&D and G&A expenses aligns with a broader industry trend of companies optimizing spending to extend cash runways, especially for firms in the clinical stage.
• The company's cash runway extending into Q1 2026 is a critical metric, as it provides a timeline for potential milestones such as BLA submission and potential approval of INO-3107.
• The DMAb technology's ability to maintain biologically relevant levels of antibodies at week 72 without anti-drug antibodies is a notable advantage compared to other gene-based delivery platforms like adeno-associated virus (AAV), which often face challenges with immunogenicity.
• Companies like Moderna and BioNTech have demonstrated the potential of mRNA technology in vaccines, and Inovio's DNA medicine platform offers a different approach with its own set of advantages and challenges.

Related Party Transactions

• The balance sheet includes accounts receivable from affiliated entity and accounts payable and accrued expenses due to affiliated entity.

Stakeholder Impact

• Positive news for patients with RRP as INO-3107 progresses towards potential approval.
• Shareholders may react positively to the progress on INO-3107 and DMAb technology, but negatively to the decreasing cash balance.
• Employees are likely to be encouraged by the company's progress and future prospects.

Next Steps

• Complete device design verification (DV) testing of the CELLECTRA device in the first half of 2025.
• Begin rolling submission of the BLA for INO-3107 in mid-2025.
• Complete the BLA submission for INO-3107 in the second half of 2025.
• Seek FDA acceptance of the BLA submission by the end of 2025.
• Present additional data from the Phase 1 trial of DMAbs at the annual meeting of the American Society of Gene and Cell Therapy in May.
• Publish data from the Phase 1 trial of DMAbs in a peer-reviewed journal.
• Continue ongoing market research with physicians, patients, and payors to support commercial readiness plans for INO-3107.

Key Dates

Keywords

INO-3107, DNA medicines, CELLECTRA, DMAbs, RRP, Inovio, BLA, Biotechnology, Financial Results